AVXL Anavex Life Sciences Corp

Price (delayed)

$2.825

Market cap

$261.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.15

Enterprise value

$143.54M

?
Relative Growth: Rel. Growth: 25
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 15

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's ...

Highlights
The company's EPS has surged by 74% YoY and by 62% QoQ
Anavex Life Sciences's net income has surged by 73% YoY and by 62% QoQ
AVXL's quick ratio has soared by 74% YoY but it is down by 15% QoQ
Anavex Life Sciences's equity has increased by 24% YoY but it has decreased by 8% QoQ

Key stats

What are the main financial stats of AVXL

AVXL stock price

How has the Anavex Life Sciences stock price performed over time
Intraday
-2.25%
1 week
-9.74%
1 month
-4.24%
1 year
-70.29%
YTD
-20.65%
QTD
9.07%

Financial performance

How have Anavex Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.37M
Net income
-$13.02M
Gross margin
N/A
Net margin
N/A
Anavex Life Sciences's net income has surged by 73% YoY and by 62% QoQ
AVXL's operating income has surged by 68% year-on-year and by 55% since the previous quarter

Price vs fundamentals

How does AVXL's price correlate with its fundamentals

Growth

What is Anavex Life Sciences's growth rate over time

Valuation

What is Anavex Life Sciences stock price valuation
P/E
N/A
P/B
2.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 74% YoY and by 62% QoQ
The stock's price to book (P/B) is 56% less than its 5-year quarterly average of 5.4 and 37% less than its last 4 quarters average of 3.8
Anavex Life Sciences's equity has increased by 24% YoY but it has decreased by 8% QoQ

Efficiency

How efficient is Anavex Life Sciences business performance
The ROE has soared by 75% YoY and by 64% from the previous quarter
AVXL's return on assets has surged by 73% year-on-year and by 63% since the previous quarter

Dividends

What is AVXL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVXL.

Financial health

How did Anavex Life Sciences financials performed over time
The company's current ratio has surged by 75% YoY but it fell by 14% QoQ
AVXL's quick ratio has soared by 74% YoY but it is down by 15% QoQ
The debt is 100% smaller than the equity
Anavex Life Sciences's equity has increased by 24% YoY but it has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.